Literature DB >> 33392892

High nuclear expression of APE1 correlates with unfavorable prognosis and promotes tumor growth in hepatocellular carcinoma.

Xiaohua Lu1, Hui Zhao1, Hongxin Yuan1, Yushan Chu1, Xiaoqing Zhu2.   

Abstract

APE1 is a multifunctional protein that plays important roles in cancer development. However, the association between APE1 expression and the clinicopathological parameters of HCC patients has not been fully characterized. In this study, bioinformatics analysis of APE1 was performed in several databases, including the TCGA, GeneCard, Human Protein Atlas and Ualcan databases. The relationship between APE1 mRNA expression and several attributes of liver cancer patients in TCGA was investigated. Then, the protein expression of APE1 was detected by IHC analysis in 95 HCC samples and the association between APE1 expression and the clinicopathological parameters of HCC patients was explored. GSEA-KEGG analysis was performed to predict the potential signaling pathways that associated with APE1 expression. Then the siRNA-mediated knockdown model of APE1 was constructed in HCC cell line to further detect the detailed function of APE1 in HCC development in vitro and in vivo. The results of the bioinformatics analysis showed that APE1 expression was primarily located in the cell nucleus. APE1 mRNA expression was substantially correlated with pathological grade and T status in TCGA database. Elevated APE1 expression was observed in HCC samples and was associated with unfavorable survival time in liver cancer patients. IHC data demonstrated that the nuclear expression of APE1 in HCC tissues was significantly higher than that in noncancerous tissues. The expression level of the APE1 protein in HCC was strongly associated with tumor diameter and overall survival. Survival analysis indicated that APE1 nuclear expression is an independent prognostic marker for the overall survival of HCC patients. GSEA-KEGG results confirmed that APE1 associated with the base excision repair signaling pathway. The data of phenotypic experiments indicated that APE1 remarkably promoted tumor growth both in HCC cells and xenografts. The findings firstly imply that nuclear expression of APE1 is a valuable prognostic marker for HCC. APE1 significantly facilitate HCC development and targeting APE1 may be a promising strategy for HCC treatment.

Entities:  

Keywords:  APE1; HCC; Prognosis; Tumorigenesis

Mesh:

Substances:

Year:  2021        PMID: 33392892     DOI: 10.1007/s10735-020-09939-9

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  28 in total

1.  Translation elongation factor eEF1Bα is identified as a novel prognostic marker of gastric cancer.

Authors:  Lizhou Jia; Tingting Yang; Xuan Gu; Wei Zhao; Qi Tang; Xudong Wang; Jin Zhu; Zhenqing Feng
Journal:  Int J Biol Macromol       Date:  2018-12-17       Impact factor: 6.953

2.  Highly expressed long non-coding RNA NNT-AS1 promotes cell proliferation and invasion through Wnt/β-catenin signaling pathway in cervical cancer.

Authors:  Fangfang Hua; Shanshan Liu; Lihong Zhu; Ning Ma; Shan Jiang; Jun Yang
Journal:  Biomed Pharmacother       Date:  2017-06-13       Impact factor: 6.529

3.  Endothelial cell tumor growth is Ape/ref-1 dependent.

Authors:  Ayan Biswas; Savita Khanna; Sashwati Roy; Xueliang Pan; Chandan K Sen; Gayle M Gordillo
Journal:  Am J Physiol Cell Physiol       Date:  2015-06-24       Impact factor: 4.249

4.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

5.  Impact of apurinic/apyrimidinic endonuclease 1/redox factor-1 on treatment response and survival in oral squamous cell carcinoma.

Authors:  Kan-Tai Hsia; Chung-Ji Liu; Kwei Mar; Li-Han Lin; Chun-Shu Lin; Ming-Fang Cheng; Herng-Sheng Lee; Shang-Yi Chiu
Journal:  Head Neck       Date:  2015-06-16       Impact factor: 3.147

6.  Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance.

Authors:  Vittorio Di Maso; Claudio Avellini; Lory Saveria Crocè; Natalia Rosso; Franco Quadrifoglio; Laura Cesaratto; Erika Codarin; Giorgio Bedogni; Carlo Alberto Beltrami; Gianluca Tell; Claudio Tiribelli
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

7.  Silencing of APE1 enhances sensitivity of human hepatocellular carcinoma cells to radiotherapy in vitro and in a xenograft model.

Authors:  Yanping Cun; Nan Dai; Chengjie Xiong; Mengxia Li; Jiangdong Sui; Chengyuan Qian; Zheng Li; Dong Wang
Journal:  PLoS One       Date:  2013-02-13       Impact factor: 3.240

Review 8.  Dynamic Regulation of APE1/Ref-1 as a Therapeutic Target Protein.

Authors:  Sunga Choi; Hee Kyoung Joo; Byeong Hwa Jeon
Journal:  Chonnam Med J       Date:  2016-05-20

9.  SESN2 correlates with advantageous prognosis in hepatocellular carcinoma.

Authors:  Shaosen Chen; Weigang Yan; Weiya Lang; Jing Yu; Li Xu; Xinyu Xu; Yunlong Liu; Hongguang Bao
Journal:  Diagn Pathol       Date:  2017-01-24       Impact factor: 2.644

10.  Exposure of Barrett's and esophageal adenocarcinoma cells to bile acids activates EGFR-STAT3 signaling axis via induction of APE1.

Authors:  Ajaz A Bhat; Heng Lu; Mohammed Soutto; Anthony Capobianco; Priyamvada Rai; Alexander Zaika; Wael El-Rifai
Journal:  Oncogene       Date:  2018-07-10       Impact factor: 9.867

View more
  1 in total

1.  Development and validation of a nomogram for predicting the cancer-specific survival of fibrolamellar hepatocellular carcinoma patients.

Authors:  Jiawei Hu; Yi Wang; Liming Deng; Haitao Yu; Kaiyu Chen; Wenming Bao; Kaiwen Chen; Gang Chen
Journal:  Updates Surg       Date:  2022-06-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.